Common hereditary cancers and implications for primary care

Lancet

Volumn 358, Issue 9275, 2001, Pages 56-63

  Emery, Jon ^a   Lucassen, Anneke ^b   Murphy, Michael ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PRINCESS ANNE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN;

BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; COLORECTAL CARCINOMA; FAMILIAL CANCER; GENE MUTATION; GENERAL PRACTITIONER; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0035822247     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)05257-0     Document Type: Review

References (71)

1. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence
2. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals
3. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%
4. The UK Northern region genetic register for familial adenomatous polyposis coli: Use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations
5. Evaluation of molecular genetic diagnosis in the management of familial adenomatous polyposis coli: A population based study
6. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review
7. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease
8. Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium
9. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients
10. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
11. Population-based study of risk of breast cancer in carriers of BRCA2 mutation
12. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer
13. Cancer risk in mutation carriers of DNA-mismatch-repair genes
14. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
15. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
16. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women - Italian Tamoxifen Prevention Study
17. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
18. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial - Multiple outcomes of Raloxifene evaluation
19. Performance of screening mammography among women with and without a first-degree relative with breast cancer
20. Screening for ovarian cancer: A pilot randomised controlled trial
21. Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations
22. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
23. Oral contraceptives and the risk of hereditary ovarian cancer
24. Epidemiology of familial adenomatous polyposis in Finland: Impact of family screening on the colorectal cancer rate and survival
25. Introduction, history and registries
26. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
27. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer
28. Chemoprevention of colorectal cancer
29. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families
30. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
31. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women
32. Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history
33. Population based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients
34. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
35. BRCA1 and BRCA2 testing: Weighing the demand against the benefits
36. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients
37. The genetics of colorectal cancer
38. Incidence of hereditary non-polyposis colorectal cancer in a population-based study of 1137 consecutive cases of colorectal cancer
39. Family history and the risk of breast cancer: A systematic review and meta-analysis
40. Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study
41. Projecting invidualised probabilities of developing breast cancer for white females who are being examined annually
42. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history
43. Assessing individual risk for breast cancer: Risky business
44. Validation of the Gail et al model for predicting individual breast cancer risk
45. Validation of a breast cancer risk assessment model in women with a positive family history
46. Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes
47. A prospective study of family history and the risk of colorectal cancer
48. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer
49. Guidelines for managing women with a family history of breast cancer
50. Hereditary nonpolyposis colorectal cancer: Review of clinical, molecular genetics, and counseling aspects
51. New clinical criteria for HNPCC proposed by the International Collaborative Group on HNPCC
52. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: Meeting highlights and Bethesda guidelines
53. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1
54. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer
55. Randomized trial of a specialist genetic assessment service for familial breast cancer
56. BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes
57. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation
58. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy
59. Efficacy of screening mammography: A meta-analysis
60. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry
61. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer
62. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: Implications for clinical predisposition testing
63. Diet and cancer preventions: The Concerted Action Polyp Prevention (CAPP) studies
64. Role of primary care providers in the delivery of genetics services
65. The prevalence of a family history of cancer in general practice
66. Cancer genetics: Survey of primary care physicians' attitudes and practices
67. A systematic review of the literature exploring the role of primary care in genetic services
68. Computer support for interpreting family histories of breast and ovarian cancer in primary care: Comparative study with simulated cases